Mucin-derived sialic acid metabolism in gut bacteria

Lead Research Organisation: Institute of Food Research
Department Name: Gut Microbes and Health


The gastrointestinal (GI) tract is colonized by a diverse community of microbes (called the gut microbiota) whose composition has a profound impact on human health. The composition of the human gut microbiota is greatly influenced by the degradation of complex dietary and host carbohydrates in the gut. Bacteria associated with the lining of the gut have the ability to forage on sugar chains provided by the mucus layer covering the GI tract.
Sialic acid or N-acetylneuraminic acid (Neu5Ac) is an abundant sugar residue found in terminal location of mucin carbohydrate chains and a key target of intestinal bacteria. Sialic acid catabolism by bacterial sialidases releases free Neu5Ac from mucins which availability in the mucosal environment drives intestinal inflammation and infection. For example, elevated levels of free sialic acid in the gut, during and post antibiotic treatments, promote the expansion of Clostridium difficile and Salmonella, as these bacteria lack a sialidase (but possess the machinery allowing the bacteria to utilise free Neu5Ac) and thus rely on free Neu5Ac released from mucins by members of the gut microbiota.
We recently discovered an unusual sialidase activity in gut commensal bacteria, which instead of releasing free Neu5Ac as in the case of hydrolytic sialidases, produces a transglycosylation product, 2,7-anhydro-Neu5Ac from mucins, which classifies this enzyme as an intramolecular trans-sialidase (IT-sialidase).
The aim of the proposal is to characterise at the molecular level how 2,7-anhydro-Neu5Ac is utilised by gut bacteria and test the hypothesis that IT-sialidase will i) provide gut bacteria with a major nutritional advantage in vivo by enabling them to produce and utilise 2,7-anhydro-Neu5Ac from mucins in a selfish manner and ii) limit enteric pathogens outgrowth by reducing the availability of Neu5Ac (and starving them as a result).

Specifically, this project aims to answer the following questions:
1. What is the pathway for 2,7-anhydro-Neu5Ac metabolism in R. gnavus?
2. Which gut bacteria are able to utilise 2,7-anhydro-Neu5Ac as sole source of nutrient?
3. Do IT-sialidases confer gut bacteria with a competitive advantage in vivo?
4. What is the impact of R. gnavus strains on the level of free sialic acid in the gut?
5. Can IT-sialidase producing strains impair S. Typhimurium colonisation in vivo?

The project is divided into 3 objectives to address these questions.

In the first objective, we will exploit our recombinant IT-sialidase to enzymatically synthesise 2,7-anhydro-Neu5Ac (not commercially available) in suitable amount to biochemically study the metabolic pathways in our model organism R. gnavus, identify and characterise the proteins involved in this process.

We will then expand this work to the gut microbiota by using a combination of bioinformatics analyses coupled with stable isotope probing (SIP) and experimental validation in vitro to identify which other commensal bacteria from the human gut are able to utilise 2,7-anhydro-Neu5Ac.

Building from our in vitro data (published and preliminary), we will then perform experiments in mouse models to determine the impact of the IT-sialidase-expressing microbes on their ability to colonise the mucosal layer, modulate the level of sialic acid in the gut, and reduce Salmonella infection.

This basic knowledge is important to explore novel anti-infective approaches as alternatives to antibiotics, which alleviate the risk of antimicrobial resistance (AMR) by modulating the mucosal environment rather than targeting the pathogen per se.

Technical Summary

The mammalian intestinal tract is protected by a mucus layer, which contains heavily glycosylated mucin proteins that comprise up to 80% carbohydrate and are often terminated by sialic acid residues. The most abundant sialic acid is N-acetylneuraminic acid (Neu5Ac) which can serve as an energy source by commensal and pathogenic bacteria. The availability of sialic acid in the mucosal compartment is particular important for the proliferation of enteropathogenic bacteria during infection. We recently discovered an usual sialidase activity in Ruminococcus gnavus, which instead of releasing free sialic acid, produces a trans-glycosylation product, 2,7-anhydro-Neu5Ac specifically from alpha-2-3-linked sialylated substrates, which classifies this enzyme as an intramolecular trans-sialidase and recently confirmed that 2,7-anhydro-Neu5Ac was used as a substrate by R. gnavus. Our bioinformatics analysis showed that IT-sialidases are predicted to occur in 11% of bacterial metagenomes examined, suggesting that bacterial IT-sialidases may play a key role in driving symbiotic host associations. This project will (1) examine the mechanisms and occurrence of IT-sialidase mediated sialic acid metabolism in gut bacteria, (2) test the hypothesis that it provides a competitive nutritional advantage to the bacteria and (3) investigate how this directly affects the level of sialic acid in the gut and impact on pathogens in vivo. Outcomes of the project will provide an enhanced understanding of sialic acid metabolism in the intestinal ecosystem and a molecular route to devise alternative strategies to antibiotics for reducing or preventing enteric infection and antimicrobial resistance.

Planned Impact

Public Health
Infectious diseases are a growing public health issue due to increasing global anti-microbial resistance (AMR). In humans, microbial infection typically starts with bacteria interacting with the mucosal surfaces which are more exposed and prone to infection. Elevated levels of sialic acid are induced by antibiotic therapy and pathogen infection. Therefore, reducing the amount of sialic acid in the mucosal environment is a novel strategy to reduce microbial infection. Currently much effort is centred upon developing new anti-microbial agents. This work will provide a completely novel approach to alleviate the risk of AMR by modulating the mucosal environment rather than targeting the pathogen per se. Within the timeframe of this study, we will focus on Salmonella for which antimicrobial resistance to cephalosporin has greatly increased. Other antibiotic-associated enteric pathogens include Clostridium difficile, an ubiquitous organism that recently emerged in animals and in humans as the main cause of nosocomial diarrhoea. In the last decade incidences of C. difficile infections (CDI) increased markedly, partly due to the use of antimicrobials, in particular cephalosporins. Future applications could target multi-drug resistant pathogens targeting other mucosal sites in the body such as Staphylococcus aureus, an ubiquitous bacterial pathogen that also uses sialic acid as nutrient source, and respiratory pathogens including Hemophilus influenzae, Streptococcus pneumoniae, or Pseudomonas aeruginosa which induce expression of sialic acid as adhesion sites. The longer-term application of this research will be designing and testing suitable routes and pharmaceutical formulations for IT-sialidase mucosal delivery depending on the site of the infection. These could include the use of pre/probiotic/synbiotic approaches in the gut or aerosol in the airways.

Carbohydrate/Enzyme biotech companies
The outcomes of this work will be of direct interest to companies commercializing novel glycoenzymes (e.g. trans-sialidases) (e.g. Prozomix, Megazyme, Nzytech) and those developing effective bioassays, glycosidase inhibitors, and carbohydrate-based diagnostics and therapeutics (e.g. Ludger; Iceni Diagnosis), or speciality carbohydrates such as sialylated oligosaccharides (e.g. Glycom, Carbosynth, Inbiose) for potential application as neutraceutical, pharmaceutical and cosmetic ingredients.

Biopharmaceutical/drug companies
The research may also be of interest to biopharmaceutical companies (e.g. GlaxoSmithKline) developing novel sialidase (or neuraminidase) inhibitors incl. Influenza neuraminidase inhibitors.

Food and Healthcare companies (Probiotics/Microbiome)
This research may also be of interest to companies interested in modulating the gut microbiome via pro/prebiotic approaches (e.g. Danone, Nestle, Yakult) but also an increasing number of biotech startups operating in the emerging gut microbiome space (e.g. MicroBiome Therapeutics, Enterome Bioscience).

Early career researcher
This project will provide a unique training opportunity for a post-doctoral scientist to work in a multidisciplinary environment spanning research Labs at IFR and UEA (BIO and ENV). There will also be opportunities for undergraduate students (from UEA) and visiting scientists to gain research experience through short-term placements. The PDRA will receive expert training in anaerobic microbiology, heterologous expression, carbohydrate biosynthesis and analysis (HPLC, MS- and NMR-based methods), enzymatic assays, bioinformatics (TGAC) and statistical analyses. The techniques are well-established and there is considerable expertise in conducting research on glycobiology and gut microbiology. There will be opportunities to collaborate with chemists and structural biologists. The PDRA will benefit from the established international network of academic and industrial collaborations of the NRP Labs.


10 25 50
Description The gastrointestinal (GI) tract is heavily colonized with bacteria (gut microbiota) which play a vital role in human health. We provided biochemical evidence for the adaptation of prevalent members of the gut microbial community to the intestinal mucus niche in heath and disease. We have unravelled a new metabolic pathway for sialic acid utilisation by gut bacteria.
Exploitation Route This mechanistic knowledge can be used for the development of novel biomarkers of disease and strategies to modulate the mucus-associated microbiome.
Sectors Pharmaceuticals and Medical Biotechnology

Description A patent application has been filed
Sector Pharmaceuticals and Medical Biotechnology
Description Development of multi-step enzymatic routes for the synthesis of sialic acid derivatives
Amount £103,000 (GBP)
Funding ID IBCarb-PoC-0315-009 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2015 
End 05/2016
Description Norwich Research Park Bioscience Doctoral Training Partnership
Amount £100,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2016 
End 09/2020
Description Norwich Research Park Bioscience Doctoral Training Partnership
Amount £100,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2015 
End 09/2019
Description Training interdisciplinary glycoscientists to get a molecular- level grip on glycocodes at the human mucosa-microbiota
Amount £466,300 (GBP)
Funding ID 814102 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2019 
End 12/2022
Description Our collaboration with Jesus Angulo at UEA led to the development of a new way of analysing how drugs interact with molecules throough adaptation of a technique known as ligand-based Nuclear Magnetic Resonance (NMR) spectroscopy 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact This method could to lead to stronger and more selective drug candidates. 
Title Membrane-enclosed multienzyme (MEME) synthesis of 2,7-anhydro-sialic acid derivatives. 
Description A facile one-pot two-enzyme approach has been established for the synthesis of 2,7-anhydro-sialic acid derivatives including those containing different sialic acid forms such as Neu5Ac and N-glycolylneuraminic acid (Neu5Gc). This synthetic method, which is based on a membrane-enclosed enzymatic synthesis, can be performed on a preparative scale. Using fetuin as a substrate, high-yield and cost-effective production of 2,7-anhydro-Neu5Ac was obtained to high-purity. This method was also applied to the synthesis of 2,7-anhydro-Neu5Gc. The membrane-enclosed multienzyme (MEME) strategy reported here provides an efficient approach to produce a variety of sialic acid derivatives. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The method allowed to produce 2,7-anhydro-sialic acid derivatives (not commercially available) in amount and purity allowing further mechanistic studies and exploring applications in the health sector 
Description Carbohydrate synthesis 
Organisation University of California
Country United States 
Sector Academic/University 
PI Contribution Utilised carbohydrates provided by collaborator in scientific research projects
Collaborator Contribution Provided bespoke carbohydrates upon request
Impact Carbohydr Res. 2017 Nov 8;451:110-117. doi: 10.1016/j.carres.2017.08.008; Nat Commun. 2017 Dec 19;8(1):2196. doi: 10.1038/s41467-017-02109-8.
Start Year 2015
Description Microbial polysaccharides 
Organisation Azienda Ospedaliera Universitaria Seconda Università di Napoli
PI Contribution Provided collaborator with bacterial samples to be analyses
Collaborator Contribution Purified bacterial cell surface polysaccharides and analysed glycosylation chemical structures
Impact Joint Abstract describing the collaborative work to Conference
Start Year 2018
Description STD-NMR 
Organisation University of East Anglia
Department Schools of Pharmacy and Medicine UEA
Country United Kingdom 
Sector Academic/University 
PI Contribution We provided proteins and ligands for analysis by STD NMR to complement some of our data on mechanisms of host-bacteria interactions. This collaboration resulted in high impact joint publications led by QIB (Proc Natl Acad Sci U S A. 2018 pii: 201715016; Nat Commun. 2017 ;8(1):2196)
Collaborator Contribution STD- NMR analysis of proteins and ligands we provided. Some of this work led to the development of DEEP STD NMR, leading to a joint publication led by UEA (Angew Chem Int Ed Engl. 2017 56:15289-15293).
Impact Proc Natl Acad Sci U S A. 2018 pii: 201715016; Nat Commun. 2017 ;8(1):2196; Angew Chem Int Ed Engl. 2017 56:15289-15293
Start Year 2014
Description Synchrotron Oxford 
Organisation Diamond Light Source
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided collaborator with proteins and ligands for X-ray crystallography and cryo-EM
Collaborator Contribution X-ray crystallography of proteins free and in complex
Impact Nat Commun. 2017 Dec 19;8(1):2196. doi: 10.1038/s41467-017-02109-8.
Start Year 2016
Description 4th Annual European Microbiome Congress 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Attendance to 4th Annual European Microbiome Congress. This Conference has a high representation from the Industry: Pharmaceutical companies and Biotechnology companies and provided an excellent opportunity to make contact and discuss work relevant to the Institute Strategic Programmes. The PROMOTING WOMEN IN SCIENCE lunch session was inspiring.
Year(s) Of Engagement Activity 2018